Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (29275)	9/13/1999 5:56:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Tonight LGND released details of a new agreement with Roche concerning using of daclizumab, a monoclonal antibody directed against the IL-2 Receptor. I assume that this is the rumored patent infringement which would add icing to the SRGN deal. For some time there had been a rumor that LGND would get additional benefits through enforcement of patents licensed by SRGN. Since Roche is agreeing to pay $2.5 million for sales BEFORE this agreement, it would seem that their Zenapax product had some interference with the "Strom Patents". It's rather ironic that LGND is collecting money from Roche. In the past some had speculated on the "Roche patent" causing a problem with Panretin. Although the patents and molecules are totally unrelated, tonight's press release makes it clear who is paying whom for patent infringements in this case.

To: bob zagorin who wrote (29275)	9/13/1999 6:25:00 PM
From: Henry Niman	Respond to of 32384

Looks like the "Strom Patents" are rather broad and go back to a 1985 filing 164.195.100.11 5,916,559 Use of interleukin-2 (IL-2) receptor-specific agents to treat allograft rejection 5,674,494 Treating non-malignant disease states with IL-2 receptor-specific substances 5,607,675 Treatment of autoimmune diseases with IL-2 receptor-specific cytotoxin 5,587,162 Treatment of allograft rejection with IL-2 receptor-specific cytotoxins 5,571,507 Methods of treating diabetes 5,510,105 Treatment of autoimmune diseases with IL-2 receptor-specific cytotoxins 5,336,489 Treatment of allograft rejection with IL-2 receptor-specific cytotoxins 5,152,980 Induction of tolerance to a foreign antigen IL-2 receptor-binding substances 5,011,684 Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance

To: bob zagorin who wrote (29275)	9/13/1999 6:43:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Phase II Clinical trial using daclizumab for autoimmune indications: Developer: Protein Design Labs Indication: Prevention of kidney transplant rejection episodes - cyclosporine elimination Marketer(s): Hoffman-La Roche Product: daclizumab + mycophenolate mofetil + corticosteroids Current Status: Phase II Tradename: Zenapax + CellCept Active Agreement(s): Disease: Autoimmune - Immunosuppressives, Transplantation Terminated Agreement(s): Technology: Monoclonals - Humanized Abs